Vistin Pharma — Earnings Release 2016

Apr 28, 2016

Vistin Pharma ASA : Strong first quarter 2016 and bright outlook

Vistin Pharma ASA : Strong first quarter 2016 and bright outlook

Oslo, Norway, 28 April 2016

Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) recorded its

highest ever revenue from its main metformin business in the first quarter of

2016. Together with strong growth in opioids and a stable, profitable contract

manufacturing business, Vistin Pharma recorded another solid quarter.

"Our growth story continues, and I am pleased to report on solid performance

within all three business segments. Demand for our metformin products continues

to exceed our current production capacity. Higher sales of codeine tablets led

to a 46 per cent growth within our opioids business, while our CMO business

continues to perform according to plan", says CEO Kjell-Erik Nordby.

Vistin Pharma recorded revenue of NOK 103.2 million in the first quarter.

Reported EBITDA was NOK 11.0 million, while the net profit came in at NOK 6.6

million.

With solid, long-term potential in all three business segments, Vistin Pharma's

ambition is to grow the Company significantly.

"The metformin business is experiencing growing demand owing to overall market

developments. Long-term drivers for the opioid market also indicate an

attractive future growth potential, and the outlook for our CMO business is

promising. Our strategy is to grow our business significantly going forward,

through investments in internal capacity expansion, completion of an operational

excellence program, and through potential M&A opportunities. I see a bright

future for Vistin Pharma", says Nordby.

Vistin Pharma will give a presentation today at 08:30 CET at Felix

Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kjell-Erik Nordby and CFO

Gunnar Manum will represent the company. The presentation will be held in

English.

The presentation will be webcast live and can be accessed directly from

http://webtv.hegnar.no/presentation.php?webcastId=33048918

or http://www.vistin.com/investors/webcast-article214-455.html.

Please find the report and presentation for the first quarter 2016 enclosed. The

report and presentation will also be made available on www.vistin.com.

For further information, please contact:

Kjell-Erik Nordby

CEO

+47 91 36 42 80

kjell-erik.nordby@vistin.com

Gunnar Manum

CFO

+47 95 17 91 90

gunnar.manum@vistin.com

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

Note: Vistin Pharma ASA was established in February 2015, and the Group had no

operating activities prior to Vistin Pharma AS' acquisition of the B2B business

and tablet production assets from Weifa AS on 1 June 2015.

About Vistin Pharma

Vistin Pharma is a Norwegian pharmaceutical company producing Active

Pharmaceutical Ingredients (APIs) and solid dosage forms for the global

pharmaceutical industry. The company has key positions in the Metformin and

Opioids markets, and a strong foundation for creating a highly efficient

Contract Manufacturing tablet production (CMO) business.  Solid growth

potentials exist in all the business segments.

With more than 65 years of pharmaceutical industry experience, Vistin Pharma has

built significant capacity and expertise as an API provider. The Company has

more than 140 highly qualified employees and two manufacturing facilities in

Kragerø, Norway. Both facilities are certified according to current Good

Manufacturing Practice (cGMP) and successfully inspected by the US Food and Drug

Administration (FDA) in 2014. Vistin Pharma's headquarter is in Oslo, Norway.

[HUG#2007462]